| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — |
| Current Ratio | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.34 |
| Quick Ratio | 0.87 | 2.48 | 1.58 | 4.65 | 6.03 | 8.47 | 13.58 | 24.34 |
| Debt / Equity | — | — | 3.63 | 0.71 | 0.30 | — | 0.00 | — |
| ROE | 2780.26% | -73.41% | -849.37% | -134.59% | -76.21% | -52.35% | -24.35% | -29.72% |
| ROA | -625.96% | -41.00% | -104.55% | -62.19% | -46.45% | -42.76% | -22.32% | -28.06% |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Book Value / Share | -0.80 | 1.84 | 0.06 | 0.70 | 1.83 | — | — | — |
BiomX Inc. is a biotechnology company focused on developing microbiome-based therapeutics using bacteriophages to target harmful bacteria. The company applies both natural and engineered phage cocktails, as well as personalized phage treatments, to address chronic conditions where specific bacterial strains play a key role. Current programs concentrate on diseases such as cystic fibrosis, where chronic pulmonary infections are common, diabetic foot osteomyelitis, and other bacterial-driven indications. BiomX uses its BOLT platform to discover and validate proprietary bacterial targets and to design customized phage compositions against them. In addition to its therapeutic pipeline, the company operates subsidiaries and units that can collaborate with partners in areas requiring advanced bio-targeting capabilities. Founded in 2015 and headquartered in Ness Ziona, Israel, BiomX Inc. occupies a specialized niche within the health technology sector, serving pharmaceutical partners, healthcare providers, and research communities seeking precision approaches to bacterial infections.